Gilead Sciences, Inc.
GILDGilead Sciences, Inc. (/ˈɡɪliəd/) is an American biopharmaceutical company headquartered in Foster City, California, that focuses on researching and developing antiviral drugs used in the treatment of HIV/AIDS, hepatitis B, hepatitis C, influenza, and COVID-19. It also develops medicines in therapeutic areas such as oncology and inflammation and cell therapy.
Drugs in Pipeline
221
Phase 3 Programs
117
Upcoming Catalysts
14
Next Catalyst
This month
Market Overview
Stock performance and key metrics
18 upcoming, 1 past
Emtricitabine/Tenofovir Disoproxil Fumarate (F/TDF) Phase 2 Est. Readout
Primary completion for Emtricitabine/Tenofovir Disoproxil Fumarate (F/TDF) trial (NCT06101329) in Pre-Exposure Prophylaxis of HIV Infection
Source17 more catalysts beyond 14 days
Start a 48-hour free trial to see all upcoming catalysts
Trodelvy
Sacituzumab Govitecan
Triple-Negative Breast Cancer
Subcutaneous (SC) Lenacapavir (LEN)
Pre-Exposure Prophylaxis of HIV Infection
ABC/DTG/3TC
HIV-1 Infection
Axicabtagene Ciloleucel
High-risk Large B-cell Lymphoma (LBCL)
ABC/3TC
HIV-1 Infection
Elvitegravir
HIV Infection
GS-4182
HIV-1-Infection
F/R/TAF
HIV-1 Infection
Stable Baseline Regimen
HIV-1-infection
Seladelpar 5 mg Capsule
Primary Biliary Cirrhosis
Remdesivir
COVID-19
Zidovudine
HIV Infections
Adefovir Dipivoxil for oral suspension, 2 mg/mL
Chronic Hepatitis B
Platinum-containing Salvage Chemotherapy
Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Tobramycin inhalation solution
Cystic Fibrosis
Lenacapavir Tablet
HIV Pre-exposure Prophylaxis
F/TAF
HIV-1 Infection
EVG/COBI/FTC/TDF
Acquired Immunodeficiency Syndrome
EFV/FTC/TDF
HIV
Subcutaneous Lenacapavir
HIV-1-infection
Metformin
Type 2 Diabetes Mellitus
AZLI 75 mg three times a day (TID)
Cystic Fibrosis
NRTIs
HIV-1 Infection
Adalimumab
Rheumatoid Arthritis
TAF
HBeAg-positive Chronic Hepatitis B
Docetaxel
Non-Small Cell Lung Cancer
RBV
Hepatitis C Virus Infection
Atripla
HIV
COBI
Acquired Immunodeficiency Syndrome
Adenosine
Coronary Artery Disease
Tenofovir disoproxil fumarate
Chronic Hepatitis B
Tobramycin Inhalation Solution (TIS)
Cystic Fibrosis
nab-Paclitaxel
Triple Negative Breast Cancer
PTM B/F/TAF
HIV-1-infection
B/F/TAF (Adult Strength)
HIV-1 Infection
FTC/RPV/TDF
HIV-1 Infection
E/C/F/TAF
HIV
Tenofovir disoproxil fumarate (TDF)
Hepatitis B Virus (HBV)
SOF
Hepatitis C
BIC/LEN FDC
HIV-1-infection
FTC/TDF
Chronic Hepatitis B
Oral Lenacapavir
HIV-1-infection
Ranolazine
Type 2 Diabetes Mellitus
AZLI
Cystic Fibrosis
Tenofovir DF
HIV Infections
B/F/TAF
HIV-1-infection
F/TDF
Pre-Exposure Prophylaxis of HIV-1 Infection
MBX-102
Type 2 Diabetes
Filgotinib
Ulcerative Colitis
Aztreonam for Inhalation Solution (AZLI)
Cystic Fibrosis
Idelalisib
Hodgkin Lymphoma
SOF/VEL
Hepatitis C Virus Infection
Sacituzumab govitecan-hziy (SG)
Triple Negative Breast Cancer
Peg-IFN
Hepatitis C
Sacituzumab Govitecan-hziy
Triple Negative Breast Cancer
Cyclophosphamide
Relapsed/Refractory Follicular Lymphoma
csDMARDs
Rheumatoid Arthritis
ADV
Chronic Hepatitis B
Lenacapavir Injection
Pre-Exposure Prophylaxis of HIV Infection
Doxorubicin
Endometrial Cancer
AmBisome
Invasive Aspergillosis
Bendamustine
Chronic Lymphocytic Leukemia
DTG
HIV-1/HBV Co-Infection
Anitocabtagene Autoleucel
Multiple Myeloma
Liposomal amphotericin B
Invasive Fungal Disease
Andecaliximab
Gastric Adenocarcinoma
Leucovorin
Gastric Adenocarcinoma
Domvanalimab
Advanced Non-Small Cell Lung Cancer
Eribulin
Metastatic Breast Cancer
E/C/F/TDF
HIV
PI
HIV-1 Infection
TDF
Chronic Hepatitis B
LDV/SOF
Chronic Hepatitis C Virus
ambrisentan
Pulmonary Hypertension
Optimized Background Regimen (OBR)
HIV-1-infection
Eribulin Mesylate Injection
Metastatic Breast Cancer
Viread (tenofovir disoproxil fumarate)
HIV Infections
KITE-753
Relapsed or Refractory Large B-cell Lymphoma
GS-1720
HIV-1-infection
AZLI 75 mg two times a day (BID)/three times a day (TID)
Cystic Fibrosis
AZLI 75 mg two times a day (BID)/ three times a day (TID)
Cystic Fibrosis
Cobicistat
Acquired Immune Deficiency Syndrome (AIDS)
SOF/VEL/VOX
Hepatitis C Virus Infection
NNRTI
Acquired Immunodeficiency Syndrome
Obeldesivir
COVID-19
PEG
Hepatitis C
Bictegravir
HIV-1-infection
Sofosbuvir
Hepatitis C, Chronic
E/C/F/TAF (Low Dose)
Acquired Immune Deficiency Syndrome (AIDS)
ISL/LEN
HIV-1-Infection
Carboplatin
Non-small Cell Lung Cancer
Bulevirtide
Chronic Hepatitis Delta
Darusentan
Hypertension
FTC
Chronic Hepatitis B
Seladelpar 10 mg
Primary Biliary Cholangitis
3rd ARV agent
HIV-1
Emtricitabine (FTC)
HIV Infections
DRV
HIV-1 Infection
Regadenoson
Coronary Artery Disease
ATV
HIV
FTC/RPV/TAF
HIV-1 Infection
Vinflunine
Locally Advanced or Metastatic Unresectable Urothelial Cancer
AZLI 75 mg three times daily (TID)
Cystic Fibrosis
3TC
HIV-1 Infection
zidovudine and lamivudine (Combivir®)
HIV Infections
MTX
Rheumatoid Arthritis
Lenacapavir
HIV Prevention
Magrolimab
Myelodysplastic Syndrome
Zimberelimab
Head and Neck Squamous Cell Carcinoma
Stribild
Acquired Immunodeficiency Syndrome
Sacituzumab Govitecan (SG)
Extensive Stage Small Cell Lung Cancer (ES-SCLC)
Paclitaxel
Locally Advanced or Unresectable Metastatic Breast Cancer
Baseline DRV- containing ARV regimen
HIV-1
seladelpar 5-10 mg
Primary Biliary Cholangitis
RTV
Acquired Immunodeficiency Syndrome
Seladelpar
Primary Biliary Cholangitis
Current failing ARV regimen
HIV
Adefovir Dipivoxil (ADV)
Chronic Hepatitis B
MBX-8025 50 mg (Dose Escalation Period 1)
Homozygous Familial Hypercholesterolemia
Tirabrutinib
Chronic Lymphocytic Leukemia
Edecesertib
Cutaneous Lupus Erythematosus (CLE)
Cetuximab
Solid Tumor
GS-9451
Hepatitis C, Chronic
KTE-C19
Refractory Diffuse Large B Cell Lymphoma
Hepatitis B virus (HBV) OAV Therapy
Chronic Hepatitis B
Ruxolitinib
Myelofibrosis
BSF 208075
Pulmonary Hypertension
D/C/F/TAF
Acquired Immunodeficiency Syndrome
GS-9876
Rheumatoid Arthritis
MBX-2044
Type 2 Diabetes Mellitus
Semaglutide
Nonalcoholic Steatohepatitis
Remdesivir (RDV)
COVID-19
Tegobuvir (GS-9190)
Hepatitis C, Chronic
GS-4321
Chronic Hepatitis Delta
Pembrolizumab
Non-small Cell Lung Cancer
Efavirenz
HIV Infections
Fludarabine
Relapsed or Refractory Large B-cell Lymphoma
Indinavir sulfate
HIV Infections
Cidofovir
Cytomegalovirus Retinitis
Febuxostat
Gout
emtricitabine /tenofovir DF
Chronic Hepatitis B
Hepatitis B Immunoglobulin (HBIg)
Chronic Hepatitis B
90Y-hPAM4
Pancreatic Cancer
radiolabeled epratuzumab
Non-Hodgkin's Lymphoma
MBX-8025
Hyperlipidemia
Colchicine
Hyperuricemia
Arhalofenate
Hyperuricemia
Tenofovir disoproxil fumarate (tenofovir DF; TDF)
Chronic Hepatitis B
Semaglutide (SEMA)
Nonalcoholic Steatohepatitis
veltuzumab
NHL
BIC
HIV-1 Infection
Abacavir
HIV
GS-9137 - A Novel HIV-1 Integrase Inhibitor
HIV
FIR
Nonalcoholic Steatohepatitis
Adefovir Dipivoxil
Hepatitis B
ISL
HIV-1 Infection
brexucabtagene autoleucel
Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia
Tenofovir Alafenamide
Chronic Hepatitis B
Nelfinavir mesylate
HIV Infections
anitocabtagene-autoleucel
Multiple Myeloma
KTE-X19
Relapsed/Refractory Mantle Cell Lymphoma
SIM
Non-Alcoholic Steatohepatitis (NASH)
Avelumab
Metastatic Urothelial Cancer
CILO
Nonalcoholic Steatohepatitis (NASH)
Pegasys®
Chronic Hepatitis C Infection
Aztreonam for Inhalation (AI)
Cystic Fibrosis
Tilpisertib Fosmecarbil
Ulcerative Colitis
Allopurinol
Gout
Dronedarone
Atrial Fibrillation
VDV
Hepatitis C Virus Infection
IMMU-107 (hPAM4)
Pancreatic Cancer
VOX
Hepatitis C Virus Infection
FTI, AZLI
Cystic Fibrosis
SEL
Diabetic Kidney Disease
Levetiracetam
Refractory Diffuse Large B Cell Lymphoma (DLBCL)
EFV
Hepatitis C
milatuzumab
Chronic Lymphocytic Lymphoma
tegobuvir capsule
Chronic Genotype 1a or 1b HCV Infection
Emtricitabine
HIV Infections
Denikitug
HER2-negative
Tegobuvir
Hepatitis C, Chronic
KITE-363
Relapsed and/or Refractory B-cell Lymphoma
Ribavirin
Hepatitis C
Simtuzumab
Primary Sclerosing Cholangitis (PSC)
Brexucabtagene Autoleucel (KTE-X19)
Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia
MBX-8025 2 mg Capsule
Primary Biliary Cirrhosis
Tecadenoson
Atrial Fibrillation
hA20-humanized anti-CD20 antibody
Non-Hodgkin's Lymphoma
OAV Regimen
Chronic HBV Infection
GS-1427
Ulcerative Colitis
abacavir 300mg twice daily
Lipodystrophy
Eleclazine
Ventricular Arrhythmia
GS-9190
HCV Infection
GS-9450
Nonalcoholic Steatohepatitis
MBX-2982
Diabetes
GS-5806
Respiratory Syncytial Virus Infections
GS-5885
Hepatitis C, Chronic
Gemcitabine
Pancreatic Cancer
Obinutuzumab
Chronic Lymphocytic Leukemia
Cilofexor
Primary Sclerosing Cholangitis
90Y-hLL2
NHL
Vesatolimod
HIV-1-infection
VEL
Hepatitis C
Teropavimab
HIV Infection
LDV
Chronic Hepatitis C Infection
EVG
HIV Infections
GS-5885 tablet
Hepatitis C, Chronic
Selonsertib
Alcoholic Hepatitis (AH)
hMN14 (labetuzumab)
Pancreatic Neoplasms
Abacavir sulfate
HIV Infections
Other approved antivirals
Chronic Hepatitis B
Selgantolimod
Chronic Hepatitis B
GS-9674
Nonalcoholic Steatohepatitis (NASH)
Zimberelimab (ZIM)
Lung Cancer
Lanraplenib
Lupus Membranous Nephropathy
Presatovir
Respiratory Syncytial Virus
GS-9669
Chronic HCV Infection
Arhalofenate 600 mg
Gout
Firsocostat
Nonalcoholic Steatohepatitis (NASH)
Emtricitabine/tenofovir disoproxil fumarate (F/TDF)
Pre-Exposure Prophylaxis of HIV Infection
GS-9256
HCV Infection
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Trodelvy Sacituzumab Govitecan | Approved | Triple-Negative Breast Cancer | Fast TrackBreakthrough | - |
Subcutaneous (SC) Lenacapavir (LEN) | Phase 3 | Pre-Exposure Prophylaxis of HIV Infection | - | - |
ABC/DTG/3TC | Phase 3 | HIV-1 Infection | - | - |
Axicabtagene Ciloleucel | Phase 3 | High-risk Large B-cell Lymphoma (LBCL) | - | - |
ABC/3TC | Phase 3 | HIV-1 Infection | - | - |
Elvitegravir | Phase 3 | HIV Infection | - | - |
GS-4182 | Phase 3 | HIV-1-Infection | - | - |
F/R/TAF | Phase 3 | HIV-1 Infection | - | - |
Stable Baseline Regimen | Phase 3 | HIV-1-infection | - | - |
Seladelpar 5 mg Capsule | Phase 3 | Primary Biliary Cirrhosis | - | - |
Remdesivir | Phase 3 | COVID-19 | - | - |
Zidovudine | Phase 3 | HIV Infections | - | - |
Adefovir Dipivoxil for oral suspension, 2 mg/mL | Phase 3 | Chronic Hepatitis B | - | - |
Platinum-containing Salvage Chemotherapy | Phase 3 | Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) | - | - |
Tobramycin inhalation solution | Phase 3 | Cystic Fibrosis | - | - |
Lenacapavir Tablet | Phase 3 | HIV Pre-exposure Prophylaxis | - | - |
F/TAF | Phase 3 | HIV-1 Infection | - | - |
EVG/COBI/FTC/TDF | Phase 3 | Acquired Immunodeficiency Syndrome | - | - |
EFV/FTC/TDF | Phase 3 | HIV | - | - |
Subcutaneous Lenacapavir | Phase 3 | HIV-1-infection | - | - |
Metformin | Phase 3 | Type 2 Diabetes Mellitus | - | - |
AZLI 75 mg three times a day (TID) | Phase 3 | Cystic Fibrosis | - | - |
NRTIs | Phase 3 | HIV-1 Infection | - | - |
Adalimumab | Phase 3 | Rheumatoid Arthritis | - | - |
TAF | Phase 3 | HBeAg-positive Chronic Hepatitis B | - | - |
Docetaxel | Phase 3 | Non-Small Cell Lung Cancer | - | - |
RBV | Phase 3 | Hepatitis C Virus Infection | - | - |
Atripla | Phase 3 | HIV | - | - |
COBI | Phase 3 | Acquired Immunodeficiency Syndrome | - | - |
Adenosine | Phase 3 | Coronary Artery Disease | - | - |
Tenofovir disoproxil fumarate | Phase 3 | Chronic Hepatitis B | - | - |
Tobramycin Inhalation Solution (TIS) | Phase 3 | Cystic Fibrosis | - | - |
nab-Paclitaxel | Phase 3 | Triple Negative Breast Cancer | - | - |
PTM B/F/TAF | Phase 3 | HIV-1-infection | - | - |
B/F/TAF (Adult Strength) | Phase 3 | HIV-1 Infection | - | - |
FTC/RPV/TDF | Phase 3 | HIV-1 Infection | - | - |
E/C/F/TAF | Phase 3 | HIV | - | - |
Tenofovir disoproxil fumarate (TDF) | Phase 3 | Hepatitis B Virus (HBV) | - | - |
SOF | Phase 3 | Hepatitis C | - | - |
BIC/LEN FDC | Phase 3 | HIV-1-infection | - | - |
FTC/TDF | Phase 3 | Chronic Hepatitis B | - | - |
Oral Lenacapavir | Phase 3 | HIV-1-infection | - | - |
Ranolazine | Phase 3 | Type 2 Diabetes Mellitus | - | - |
AZLI | Phase 3 | Cystic Fibrosis | - | - |
Tenofovir DF | Phase 3 | HIV Infections | - | - |
B/F/TAF | Phase 3 | HIV-1-infection | - | - |
F/TDF | Phase 3 | Pre-Exposure Prophylaxis of HIV-1 Infection | - | - |
MBX-102 | Phase 3 | Type 2 Diabetes | - | - |
Filgotinib | Phase 3 | Ulcerative Colitis | - | - |
Aztreonam for Inhalation Solution (AZLI) | Phase 3 | Cystic Fibrosis | - | - |
Idelalisib | Phase 3 | Hodgkin Lymphoma | - | - |
SOF/VEL | Phase 3 | Hepatitis C Virus Infection | - | - |
Sacituzumab govitecan-hziy (SG) | Phase 3 | Triple Negative Breast Cancer | - | - |
Peg-IFN | Phase 3 | Hepatitis C | - | - |
Sacituzumab Govitecan-hziy | Phase 3 | Triple Negative Breast Cancer | - | - |
Cyclophosphamide | Phase 3 | Relapsed/Refractory Follicular Lymphoma | - | - |
csDMARDs | Phase 3 | Rheumatoid Arthritis | - | - |
ADV | Phase 3 | Chronic Hepatitis B | - | - |
Lenacapavir Injection | Phase 3 | Pre-Exposure Prophylaxis of HIV Infection | - | - |
Doxorubicin | Phase 3 | Endometrial Cancer | - | - |
AmBisome | Phase 3 | Invasive Aspergillosis | - | - |
Bendamustine | Phase 3 | Chronic Lymphocytic Leukemia | - | - |
DTG | Phase 3 | HIV-1/HBV Co-Infection | - | - |
Anitocabtagene Autoleucel | Phase 3 | Multiple Myeloma | - | - |
Liposomal amphotericin B | Phase 3 | Invasive Fungal Disease | - | - |
Andecaliximab | Phase 3 | Gastric Adenocarcinoma | - | - |
Leucovorin | Phase 3 | Gastric Adenocarcinoma | - | - |
Domvanalimab | Phase 3 | Advanced Non-Small Cell Lung Cancer | - | - |
Eribulin | Phase 3 | Metastatic Breast Cancer | - | - |
E/C/F/TDF | Phase 3 | HIV | - | - |
PI | Phase 3 | HIV-1 Infection | - | - |
TDF | Phase 3 | Chronic Hepatitis B | - | - |
LDV/SOF | Phase 3 | Chronic Hepatitis C Virus | - | - |
ambrisentan | Phase 3 | Pulmonary Hypertension | - | - |
Optimized Background Regimen (OBR) | Phase 3 | HIV-1-infection | - | - |
Eribulin Mesylate Injection | Phase 3 | Metastatic Breast Cancer | - | - |
Viread (tenofovir disoproxil fumarate) | Phase 3 | HIV Infections | - | - |
KITE-753 | Phase 3 | Relapsed or Refractory Large B-cell Lymphoma | - | - |
GS-1720 | Phase 3 | HIV-1-infection | - | - |
AZLI 75 mg two times a day (BID)/three times a day (TID) | Phase 3 | Cystic Fibrosis | - | - |
AZLI 75 mg two times a day (BID)/ three times a day (TID) | Phase 3 | Cystic Fibrosis | - | - |
Cobicistat | Phase 3 | Acquired Immune Deficiency Syndrome (AIDS) | - | - |
SOF/VEL/VOX | Phase 3 | Hepatitis C Virus Infection | - | - |
NNRTI | Phase 3 | Acquired Immunodeficiency Syndrome | - | - |
Obeldesivir | Phase 3 | COVID-19 | - | - |
PEG | Phase 3 | Hepatitis C | - | - |
Bictegravir | Phase 3 | HIV-1-infection | - | - |
Sofosbuvir | Phase 3 | Hepatitis C, Chronic | - | - |
E/C/F/TAF (Low Dose) | Phase 3 | Acquired Immune Deficiency Syndrome (AIDS) | - | - |
ISL/LEN | Phase 3 | HIV-1-Infection | - | - |
Carboplatin | Phase 3 | Non-small Cell Lung Cancer | - | - |
Bulevirtide | Phase 3 | Chronic Hepatitis Delta | - | - |
Darusentan | Phase 3 | Hypertension | - | - |
FTC | Phase 3 | Chronic Hepatitis B | - | - |
Seladelpar 10 mg | Phase 3 | Primary Biliary Cholangitis | - | - |
3rd ARV agent | Phase 3 | HIV-1 | - | - |
Emtricitabine (FTC) | Phase 3 | HIV Infections | - | - |
DRV | Phase 3 | HIV-1 Infection | - | - |
Regadenoson | Phase 3 | Coronary Artery Disease | - | - |
ATV | Phase 3 | HIV | - | - |
FTC/RPV/TAF | Phase 3 | HIV-1 Infection | - | - |
Vinflunine | Phase 3 | Locally Advanced or Metastatic Unresectable Urothelial Cancer | - | - |
AZLI 75 mg three times daily (TID) | Phase 3 | Cystic Fibrosis | - | - |
3TC | Phase 3 | HIV-1 Infection | - | - |
zidovudine and lamivudine (Combivir®) | Phase 3 | HIV Infections | - | - |
MTX | Phase 3 | Rheumatoid Arthritis | - | - |
Lenacapavir | Phase 3 | HIV Prevention | Fast TrackBreakthrough | Patent 2041 |
Magrolimab | Phase 3 | Myelodysplastic Syndrome | OrphanFast TrackBreakthrough | - |
Zimberelimab | Phase 3 | Head and Neck Squamous Cell Carcinoma | - | - |
Stribild | Phase 3 | Acquired Immunodeficiency Syndrome | - | - |
Sacituzumab Govitecan (SG) | Phase 3 | Extensive Stage Small Cell Lung Cancer (ES-SCLC) | - | - |
Paclitaxel | Phase 3 | Locally Advanced or Unresectable Metastatic Breast Cancer | - | - |
Baseline DRV- containing ARV regimen | Phase 3 | HIV-1 | - | - |
seladelpar 5-10 mg | Phase 3 | Primary Biliary Cholangitis | - | - |
RTV | Phase 3 | Acquired Immunodeficiency Syndrome | - | - |
Seladelpar | Phase 3 | Primary Biliary Cholangitis | - | - |
Current failing ARV regimen | Phase 3 | HIV | - | - |
Adefovir Dipivoxil (ADV) | Phase 3 | Chronic Hepatitis B | - | - |
MBX-8025 50 mg (Dose Escalation Period 1) | Phase 2 | Homozygous Familial Hypercholesterolemia | - | - |
Tirabrutinib | Phase 2 | Chronic Lymphocytic Leukemia | - | - |
Edecesertib | Phase 2 | Cutaneous Lupus Erythematosus (CLE) | - | - |
Cetuximab | Phase 2 | Solid Tumor | - | - |
GS-9451 | Phase 2 | Hepatitis C, Chronic | - | - |
KTE-C19 | Phase 2 | Refractory Diffuse Large B Cell Lymphoma | - | - |
Hepatitis B virus (HBV) OAV Therapy | Phase 2 | Chronic Hepatitis B | - | - |
Ruxolitinib | Phase 2 | Myelofibrosis | - | - |
BSF 208075 | Phase 2 | Pulmonary Hypertension | - | - |
D/C/F/TAF | Phase 2 | Acquired Immunodeficiency Syndrome | - | - |
GS-9876 | Phase 2 | Rheumatoid Arthritis | - | - |
MBX-2044 | Phase 2 | Type 2 Diabetes Mellitus | - | - |
Semaglutide | Phase 2 | Nonalcoholic Steatohepatitis | - | - |
Remdesivir (RDV) | Phase 2 | COVID-19 | - | - |
Tegobuvir (GS-9190) | Phase 2 | Hepatitis C, Chronic | - | - |
GS-4321 | Phase 2 | Chronic Hepatitis Delta | - | - |
Pembrolizumab | Phase 2 | Non-small Cell Lung Cancer | - | - |
Efavirenz | Phase 2 | HIV Infections | - | - |
Fludarabine | Phase 2 | Relapsed or Refractory Large B-cell Lymphoma | - | - |
Indinavir sulfate | Phase 2 | HIV Infections | - | - |
Cidofovir | Phase 2 | Cytomegalovirus Retinitis | - | - |
Febuxostat | Phase 2 | Gout | - | - |
emtricitabine /tenofovir DF | Phase 2 | Chronic Hepatitis B | - | - |
Hepatitis B Immunoglobulin (HBIg) | Phase 2 | Chronic Hepatitis B | - | - |
90Y-hPAM4 | Phase 2 | Pancreatic Cancer | - | - |
radiolabeled epratuzumab | Phase 2 | Non-Hodgkin's Lymphoma | - | - |
MBX-8025 | Phase 2 | Hyperlipidemia | - | - |
Colchicine | Phase 2 | Hyperuricemia | - | - |
Arhalofenate | Phase 2 | Hyperuricemia | - | - |
Tenofovir disoproxil fumarate (tenofovir DF; TDF) | Phase 2 | Chronic Hepatitis B | - | - |
Semaglutide (SEMA) | Phase 2 | Nonalcoholic Steatohepatitis | - | - |
veltuzumab | Phase 2 | NHL | - | - |
BIC | Phase 2 | HIV-1 Infection | - | - |
Abacavir | Phase 2 | HIV | - | - |
GS-9137 - A Novel HIV-1 Integrase Inhibitor | Phase 2 | HIV | - | - |
FIR | Phase 2 | Nonalcoholic Steatohepatitis | - | - |
Adefovir Dipivoxil | Phase 2 | Hepatitis B | - | - |
ISL | Phase 2 | HIV-1 Infection | - | - |
brexucabtagene autoleucel | Phase 2 | Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia | - | - |
Tenofovir Alafenamide | Phase 2 | Chronic Hepatitis B | - | - |
Nelfinavir mesylate | Phase 2 | HIV Infections | - | - |
anitocabtagene-autoleucel | Phase 2 | Multiple Myeloma | - | - |
KTE-X19 | Phase 2 | Relapsed/Refractory Mantle Cell Lymphoma | - | - |
SIM | Phase 2 | Non-Alcoholic Steatohepatitis (NASH) | - | - |
Avelumab | Phase 2 | Metastatic Urothelial Cancer | - | - |
CILO | Phase 2 | Nonalcoholic Steatohepatitis (NASH) | - | - |
Pegasys® | Phase 2 | Chronic Hepatitis C Infection | - | - |
Aztreonam for Inhalation (AI) | Phase 2 | Cystic Fibrosis | - | - |
Tilpisertib Fosmecarbil | Phase 2 | Ulcerative Colitis | - | - |
Allopurinol | Phase 2 | Gout | - | - |
Dronedarone | Phase 2 | Atrial Fibrillation | - | - |
VDV | Phase 2 | Hepatitis C Virus Infection | - | - |
IMMU-107 (hPAM4) | Phase 2 | Pancreatic Cancer | - | - |
VOX | Phase 2 | Hepatitis C Virus Infection | - | - |
FTI, AZLI | Phase 2 | Cystic Fibrosis | - | - |
SEL | Phase 2 | Diabetic Kidney Disease | - | - |
Levetiracetam | Phase 2 | Refractory Diffuse Large B Cell Lymphoma (DLBCL) | - | - |
EFV | Phase 2 | Hepatitis C | - | - |
milatuzumab | Phase 2 | Chronic Lymphocytic Lymphoma | - | - |
tegobuvir capsule | Phase 2 | Chronic Genotype 1a or 1b HCV Infection | - | - |
Emtricitabine | Phase 2 | HIV Infections | - | - |
Denikitug | Phase 2 | HER2-negative | - | - |
Tegobuvir | Phase 2 | Hepatitis C, Chronic | - | - |
KITE-363 | Phase 2 | Relapsed and/or Refractory B-cell Lymphoma | - | - |
Ribavirin | Phase 2 | Hepatitis C | - | - |
Simtuzumab | Phase 2 | Primary Sclerosing Cholangitis (PSC) | - | - |
Brexucabtagene Autoleucel (KTE-X19) | Phase 2 | Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia | - | - |
MBX-8025 2 mg Capsule | Phase 2 | Primary Biliary Cirrhosis | - | - |
Tecadenoson | Phase 2 | Atrial Fibrillation | - | - |
hA20-humanized anti-CD20 antibody | Phase 2 | Non-Hodgkin's Lymphoma | - | - |
OAV Regimen | Phase 2 | Chronic HBV Infection | - | - |
GS-1427 | Phase 2 | Ulcerative Colitis | - | - |
abacavir 300mg twice daily | Phase 2 | Lipodystrophy | - | - |
Eleclazine | Phase 2 | Ventricular Arrhythmia | - | - |
GS-9190 | Phase 2 | HCV Infection | - | - |
GS-9450 | Phase 2 | Nonalcoholic Steatohepatitis | - | - |
MBX-2982 | Phase 2 | Diabetes | - | - |
GS-5806 | Phase 2 | Respiratory Syncytial Virus Infections | - | - |
GS-5885 | Phase 2 | Hepatitis C, Chronic | - | - |
Gemcitabine | Phase 2 | Pancreatic Cancer | - | - |
Obinutuzumab | Phase 2 | Chronic Lymphocytic Leukemia | - | - |
Cilofexor | Phase 2 | Primary Sclerosing Cholangitis | - | - |
90Y-hLL2 | Phase 2 | NHL | - | - |
Vesatolimod | Phase 2 | HIV-1-infection | - | - |
VEL | Phase 2 | Hepatitis C | - | - |
Teropavimab | Phase 2 | HIV Infection | - | - |
LDV | Phase 2 | Chronic Hepatitis C Infection | - | - |
EVG | Phase 2 | HIV Infections | - | - |
GS-5885 tablet | Phase 2 | Hepatitis C, Chronic | - | - |
Selonsertib | Phase 2 | Alcoholic Hepatitis (AH) | - | - |
hMN14 (labetuzumab) | Phase 2 | Pancreatic Neoplasms | - | - |
Abacavir sulfate | Phase 2 | HIV Infections | - | - |
Other approved antivirals | Phase 2 | Chronic Hepatitis B | - | - |
Selgantolimod | Phase 2 | Chronic Hepatitis B | - | - |
GS-9674 | Phase 2 | Nonalcoholic Steatohepatitis (NASH) | - | - |
Zimberelimab (ZIM) | Phase 2 | Lung Cancer | - | - |
Lanraplenib | Phase 2 | Lupus Membranous Nephropathy | - | - |
Presatovir | Phase 2 | Respiratory Syncytial Virus | - | - |
GS-9669 | Phase 2 | Chronic HCV Infection | - | - |
Arhalofenate 600 mg | Phase 2 | Gout | - | - |
Firsocostat | Phase 2 | Nonalcoholic Steatohepatitis (NASH) | - | - |
Emtricitabine/tenofovir disoproxil fumarate (F/TDF) | Phase 2 | Pre-Exposure Prophylaxis of HIV Infection | - | - |
GS-9256 | Phase 2 | HCV Infection | - | - |
Triple-Negative Breast Cancer
1 drug in this indication
HIV Prevention
1 drug in this indication
Myelodysplastic Syndrome
1 drug in this indication
Rheumatoid Arthritis
1 drug in this indication
Solid Tumor
1 drug in this indication
Hepatitis C, Chronic
1 drug in this indication
Refractory Diffuse Large B Cell Lymphoma
1 drug in this indication
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Gilead Sciences, Inc.'s drug pipeline?→
CatalystAlert tracks 221 drug candidates in Gilead Sciences, Inc.'s (GILD) pipeline across Phase 3, Phase 2, Approved. Its lead program is Subcutaneous (SC) Lenacapavir (LEN) (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Gilead Sciences, Inc.'s next FDA catalyst?→
Gilead Sciences, Inc.'s (GILD) next tracked catalyst is a Phase 2 expected July 15, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track GILD biotech catalysts?→
Add GILD to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Gilead Sciences, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.